Press release
United Therapeutics Releases its Annual Corporate Responsibility Report
Report available at corporateresponsibility.unither.com SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2021 /PRNewswire/ -- United
About this update from United Therapeutics Corporation
[{"type":"text","content":"Report available at corporateresponsibility.unither.com\n\n\n SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its second annual Corporate Responsibility Report with 2020 highlights, providing stakeholders important information regarding the company's commitment to environmental, social, and governance (ESG) priorities. \n\"Since our inception – before the term 'ESG' was coined – we've been focused on environmental sensitivity, social leadership, and innovative governance as part of our day-to-day operations,\" said Dewey Steadman, Head of Investor Relations and ESG Transparency Lead at United Therapeutics. \"Our second annual Corporate Responsibility Report represents a progression in our transparency efforts around corporate responsibility that solidifies our position as a leader in ESG management.\"\nUnited Therapeutics developed its Corporate Responsibility Report utilizing the frameworks provided by both the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and the Task Force on Climate-Related Financial Disclosures (TCFD). United Therapeutics is using applicable GRI, SASB, and TCFD metrics to measure its performance. \nFind the full report at corporateresponsibility.unither.com.\nUnited Therapeutics: Enabling InspirationUnited Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.\nThrough our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.\nPlease visit unither.com to learn more.\nForward-looking StatementsStatements included in this press ...